Cetuximab-Induced Acneiform Eruption: A Case Report
Turkish Journal of Internal Medicine · 2022
DOI: 10.46310/tjim.1071185 ↗At a glance
Fallbericht in Turkish Journal of Internal Medicine, 2022. Written by Büşra GÜNER and 2 co-authors. 7 references.
Abstract (original language)
Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.
Cite
APA
GÜNER, B., EVRENSEL, T., & ORHAN, S. O. (2022). Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1071185
Vancouver
GÜNER B, EVRENSEL T, ORHAN SO. Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1071185
BibTeX
@article{GNER2022,
author = {GÜNER, Büşra and EVRENSEL, Türkkan and ORHAN, Sibel OYUCU},
title = {Cetuximab-Induced Acneiform Eruption: A Case Report},
journal = {Turkish Journal of Internal Medicine},
year = {2022},
doi = {10.46310/tjim.1071185}
}
EUVIMED